Patent 10336722 was granted and assigned to FORMA Therapeutics on July, 2019 by the United States Patent and Trademark Office.
The present invention relates to inhibitors of bromo and extra terminal (BET) bromodomains that are useful for the treatment of cancer, inflammatory diseases, diabetes, and obesity, having Formula I: